Recommendations for myasthenia gravis clinical trials

Michael Benatar, Donald B. Sanders, Ted M. Burns, Gary R. Cutter, Jeffrey T. Guptill, Fulvio Baggi, Henry J. Kaminski, Renato Mantegazza, Matthew N. Meriggioli, Joanne Quan, Gil I. Wolfe, Richard J. Barohn, Ted M. Burns, Gary R. Cutter, Jeffrey T. Guptill, James F. Howard, Henry J. Kaminski, Renato Mantegazza, Matthew N. Merrigioli, Steven PiantadosiAlexis Smirnow, Gil I. Wolfe

Research output: Contribution to journalArticle

Abstract

The recommendations for clinical research standards published in 2000 by a task force of the Medical Scientific Advisory Board (MSAB) of the Myasthenia Gravis Foundation of America (MGFA) were largely successful in introducing greater uniformity in the recording and reporting of MG clinical trials. Recognizing that changes in clinical trial design and implementation may increase the likelihood that new therapies are developed for MG, the MGFA MSAB Task Force here presents updated recommendations for the design and implementation of clinical trials in MG, including (a) the use of a quantitative measure, such as the MG-Composite, that is weighted for clinical significance and incorporates patient reported outcomes; (b) consideration of nontrial strategies; and (c) development of biomarkers that support mechanistic studies of pharmacotherapies. The hope is that these updated task force recommendations will expedite the development and acceptance of more effective and less noxious therapies for MG.

Original languageEnglish (US)
Pages (from-to)909-917
Number of pages9
JournalMuscle and Nerve
Volume45
Issue number6
DOIs
StatePublished - Jun 2012
Externally publishedYes

Fingerprint

Myasthenia Gravis
Advisory Committees
Clinical Trials
Biomarkers
Drug Therapy
Therapeutics
Research

Keywords

  • All clinical trials
  • Clinical trials methodology/study design
  • Myasthenia
  • Outcome measures
  • Quality of life

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)
  • Physiology

Cite this

Benatar, M., Sanders, D. B., Burns, T. M., Cutter, G. R., Guptill, J. T., Baggi, F., ... Wolfe, G. I. (2012). Recommendations for myasthenia gravis clinical trials. Muscle and Nerve, 45(6), 909-917. https://doi.org/10.1002/mus.23330

Recommendations for myasthenia gravis clinical trials. / Benatar, Michael; Sanders, Donald B.; Burns, Ted M.; Cutter, Gary R.; Guptill, Jeffrey T.; Baggi, Fulvio; Kaminski, Henry J.; Mantegazza, Renato; Meriggioli, Matthew N.; Quan, Joanne; Wolfe, Gil I.; Barohn, Richard J.; Burns, Ted M.; Cutter, Gary R.; Guptill, Jeffrey T.; Howard, James F.; Kaminski, Henry J.; Mantegazza, Renato; Merrigioli, Matthew N.; Piantadosi, Steven; Smirnow, Alexis; Wolfe, Gil I.

In: Muscle and Nerve, Vol. 45, No. 6, 06.2012, p. 909-917.

Research output: Contribution to journalArticle

Benatar, M, Sanders, DB, Burns, TM, Cutter, GR, Guptill, JT, Baggi, F, Kaminski, HJ, Mantegazza, R, Meriggioli, MN, Quan, J, Wolfe, GI, Barohn, RJ, Burns, TM, Cutter, GR, Guptill, JT, Howard, JF, Kaminski, HJ, Mantegazza, R, Merrigioli, MN, Piantadosi, S, Smirnow, A & Wolfe, GI 2012, 'Recommendations for myasthenia gravis clinical trials', Muscle and Nerve, vol. 45, no. 6, pp. 909-917. https://doi.org/10.1002/mus.23330
Benatar M, Sanders DB, Burns TM, Cutter GR, Guptill JT, Baggi F et al. Recommendations for myasthenia gravis clinical trials. Muscle and Nerve. 2012 Jun;45(6):909-917. https://doi.org/10.1002/mus.23330
Benatar, Michael ; Sanders, Donald B. ; Burns, Ted M. ; Cutter, Gary R. ; Guptill, Jeffrey T. ; Baggi, Fulvio ; Kaminski, Henry J. ; Mantegazza, Renato ; Meriggioli, Matthew N. ; Quan, Joanne ; Wolfe, Gil I. ; Barohn, Richard J. ; Burns, Ted M. ; Cutter, Gary R. ; Guptill, Jeffrey T. ; Howard, James F. ; Kaminski, Henry J. ; Mantegazza, Renato ; Merrigioli, Matthew N. ; Piantadosi, Steven ; Smirnow, Alexis ; Wolfe, Gil I. / Recommendations for myasthenia gravis clinical trials. In: Muscle and Nerve. 2012 ; Vol. 45, No. 6. pp. 909-917.
@article{6e00b4b572014e299fe932c61ac2b79f,
title = "Recommendations for myasthenia gravis clinical trials",
abstract = "The recommendations for clinical research standards published in 2000 by a task force of the Medical Scientific Advisory Board (MSAB) of the Myasthenia Gravis Foundation of America (MGFA) were largely successful in introducing greater uniformity in the recording and reporting of MG clinical trials. Recognizing that changes in clinical trial design and implementation may increase the likelihood that new therapies are developed for MG, the MGFA MSAB Task Force here presents updated recommendations for the design and implementation of clinical trials in MG, including (a) the use of a quantitative measure, such as the MG-Composite, that is weighted for clinical significance and incorporates patient reported outcomes; (b) consideration of nontrial strategies; and (c) development of biomarkers that support mechanistic studies of pharmacotherapies. The hope is that these updated task force recommendations will expedite the development and acceptance of more effective and less noxious therapies for MG.",
keywords = "All clinical trials, Clinical trials methodology/study design, Myasthenia, Outcome measures, Quality of life",
author = "Michael Benatar and Sanders, {Donald B.} and Burns, {Ted M.} and Cutter, {Gary R.} and Guptill, {Jeffrey T.} and Fulvio Baggi and Kaminski, {Henry J.} and Renato Mantegazza and Meriggioli, {Matthew N.} and Joanne Quan and Wolfe, {Gil I.} and Barohn, {Richard J.} and Burns, {Ted M.} and Cutter, {Gary R.} and Guptill, {Jeffrey T.} and Howard, {James F.} and Kaminski, {Henry J.} and Renato Mantegazza and Merrigioli, {Matthew N.} and Steven Piantadosi and Alexis Smirnow and Wolfe, {Gil I.}",
year = "2012",
month = "6",
doi = "10.1002/mus.23330",
language = "English (US)",
volume = "45",
pages = "909--917",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Recommendations for myasthenia gravis clinical trials

AU - Benatar, Michael

AU - Sanders, Donald B.

AU - Burns, Ted M.

AU - Cutter, Gary R.

AU - Guptill, Jeffrey T.

AU - Baggi, Fulvio

AU - Kaminski, Henry J.

AU - Mantegazza, Renato

AU - Meriggioli, Matthew N.

AU - Quan, Joanne

AU - Wolfe, Gil I.

AU - Barohn, Richard J.

AU - Burns, Ted M.

AU - Cutter, Gary R.

AU - Guptill, Jeffrey T.

AU - Howard, James F.

AU - Kaminski, Henry J.

AU - Mantegazza, Renato

AU - Merrigioli, Matthew N.

AU - Piantadosi, Steven

AU - Smirnow, Alexis

AU - Wolfe, Gil I.

PY - 2012/6

Y1 - 2012/6

N2 - The recommendations for clinical research standards published in 2000 by a task force of the Medical Scientific Advisory Board (MSAB) of the Myasthenia Gravis Foundation of America (MGFA) were largely successful in introducing greater uniformity in the recording and reporting of MG clinical trials. Recognizing that changes in clinical trial design and implementation may increase the likelihood that new therapies are developed for MG, the MGFA MSAB Task Force here presents updated recommendations for the design and implementation of clinical trials in MG, including (a) the use of a quantitative measure, such as the MG-Composite, that is weighted for clinical significance and incorporates patient reported outcomes; (b) consideration of nontrial strategies; and (c) development of biomarkers that support mechanistic studies of pharmacotherapies. The hope is that these updated task force recommendations will expedite the development and acceptance of more effective and less noxious therapies for MG.

AB - The recommendations for clinical research standards published in 2000 by a task force of the Medical Scientific Advisory Board (MSAB) of the Myasthenia Gravis Foundation of America (MGFA) were largely successful in introducing greater uniformity in the recording and reporting of MG clinical trials. Recognizing that changes in clinical trial design and implementation may increase the likelihood that new therapies are developed for MG, the MGFA MSAB Task Force here presents updated recommendations for the design and implementation of clinical trials in MG, including (a) the use of a quantitative measure, such as the MG-Composite, that is weighted for clinical significance and incorporates patient reported outcomes; (b) consideration of nontrial strategies; and (c) development of biomarkers that support mechanistic studies of pharmacotherapies. The hope is that these updated task force recommendations will expedite the development and acceptance of more effective and less noxious therapies for MG.

KW - All clinical trials

KW - Clinical trials methodology/study design

KW - Myasthenia

KW - Outcome measures

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=84860897376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860897376&partnerID=8YFLogxK

U2 - 10.1002/mus.23330

DO - 10.1002/mus.23330

M3 - Article

C2 - 22581550

AN - SCOPUS:84860897376

VL - 45

SP - 909

EP - 917

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 6

ER -